Intervacc AB (IVACC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Intervacc AB (IVACC) has a cash flow conversion efficiency ratio of -0.094x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-29.33 Million ≈ $-3.16 Million USD) by net assets (Skr310.46 Million ≈ $33.41 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Intervacc AB - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Intervacc AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Intervacc AB for a breakdown of total debt and financial obligations.
Intervacc AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intervacc AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Actoz Soft Co.Ltd
KQ:052790
|
0.050x |
|
Eclipse Metals Ltd
AU:EPM
|
-0.064x |
|
Far East Fame Line DDB Public Company Limited
BK:FE
|
0.005x |
|
Firetrade Engineering PCL
BK:FTE
|
0.045x |
|
GROUP PAREF INH. EO 25
F:G5I
|
N/A |
|
Australian Unity Office Fund
AU:AOF
|
-0.011x |
|
White Pearl Technology Group B
ST:WPTG-B
|
N/A |
|
Done.ai Group AB
ST:TINGS-B
|
0.025x |
Annual Cash Flow Conversion Efficiency for Intervacc AB (2015–2024)
The table below shows the annual cash flow conversion efficiency of Intervacc AB from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Intervacc AB stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr162.33 Million ≈ $17.47 Million |
Skr-53.20 Million ≈ $-5.72 Million |
-0.328x | -70.11% |
| 2023-12-31 | Skr237.93 Million ≈ $25.61 Million |
Skr-45.83 Million ≈ $-4.93 Million |
-0.193x | +30.95% |
| 2022-12-31 | Skr250.16 Million ≈ $26.92 Million |
Skr-69.79 Million ≈ $-7.51 Million |
-0.279x | -237.73% |
| 2021-12-31 | Skr308.25 Million ≈ $33.17 Million |
Skr-25.46 Million ≈ $-2.74 Million |
-0.083x | -38.88% |
| 2020-12-31 | Skr337.61 Million ≈ $36.33 Million |
Skr-20.08 Million ≈ $-2.16 Million |
-0.059x | -372.02% |
| 2019-12-31 | Skr219.82 Million ≈ $23.66 Million |
Skr-2.77 Million ≈ $-298.10K |
-0.013x | +40.50% |
| 2018-12-31 | Skr190.43 Million ≈ $20.49 Million |
Skr-4.03 Million ≈ $-434.02K |
-0.021x | +81.77% |
| 2017-12-31 | Skr164.90 Million ≈ $17.75 Million |
Skr-19.16 Million ≈ $-2.06 Million |
-0.116x | -260.12% |
| 2016-12-31 | Skr130.18 Million ≈ $14.01 Million |
Skr-4.20 Million ≈ $-451.99K |
-0.032x | +78.61% |
| 2015-12-31 | Skr126.52 Million ≈ $13.62 Million |
Skr-19.09 Million ≈ $-2.05 Million |
-0.151x | -- |
About Intervacc AB
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages… Read more